Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg^-1 rifampicin.

ABSTRACT:

Background

Accumulating data indicate that higher rifampicin doses are more effective and shorten tuberculosis (TB) treatment duration. This study evaluated the safety, tolerability, pharmacokinetics, and 7- and 14-day early bactericidal activity (EBA) of increasing doses of rifampicin. Here we report the results of the final cohorts of PanACEA HIGHRIF1, a dose escalation study in treatment-naive adult smear-positive patients with TB.

Methods

Patients received, in consecutive cohorts, 40 or 50 mg·kg^-1 rifampicin once daily in monotherapy (day 1-7), supplemented with standard dose isoniazid, pyrazinamide and ethambutol between days 8 and 14.

Results

In the 40 mg·kg^-1 cohort (n=15), 13 patients experienced a total of 36 adverse events during monoth

SUBMITTER: Te Brake LHM 

PROVIDER: S-EPMC8411896 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature